NAUD: Neurobiology of Alcohol and Nicotine Co-Addiction
Study Details
Study Description
Brief Summary
This proposal addresses the critical absence of information about the neurobiology of recovery from Alcohol Use Disorder (AUD) in alcohol and nicotine users.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This proposal addresses the critical absence of information about the neurobiology of recovery from Alcohol Use Disorder (AUD) in alcohol and nicotine users. AUD and nicotine use disorder (NUD) are the most commonly abused (non-prescription) substances in the U.S. Co-addiction is particularly high in military veterans. Although nationwide estimates peg the rate of AUD/NUD co-addiction at 80%, the Substance Abuse Treatment Program (SATP) at the Veterans Affairs Portland Health Care System (VAPORHCS) finds that 90% of veterans treated for AUD also meet criteria for NUD. The investigators hypothesize that a support vector machine learning algorithm will be able to use the measures to classify subjects as AUD, NUD both or neither and that the algorithm will predict outcome (sobriety or relapse) at three months.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Control Group No history of addiction to any substance or gambling. Less than 20 lifetime cigarettes or equivalent. |
Behavioral: magnetic resonance imaging (MRI)
All subjects will undergo a baseline MRI and subjects in both alcohol groups (alcohol use disorder and combined alcohol and nicotine use disorder) will undergo a followup MRI 3 months after baseline.
|
| Nicotine Group Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V) criteria for Nicotine Use Disorder. Current smoker, at least 10 cigarettes per day. No history of addiction to any other substance |
Behavioral: magnetic resonance imaging (MRI)
All subjects will undergo a baseline MRI and subjects in both alcohol groups (alcohol use disorder and combined alcohol and nicotine use disorder) will undergo a followup MRI 3 months after baseline.
|
| Nicotine and Alcohol Group DSM-V criteria for Nicotine Use Disorder and Alcohol Use Disorder. At least 8 heavy drinking episodes in the past month. Current smoker. Alcohol free from 2 to 4 weeks. No history of addiction to other substances or gambling. |
Behavioral: magnetic resonance imaging (MRI)
All subjects will undergo a baseline MRI and subjects in both alcohol groups (alcohol use disorder and combined alcohol and nicotine use disorder) will undergo a followup MRI 3 months after baseline.
|
| Alcohol Group DSM-V criteria for Alcohol use Disorder. At least 8 heavy drinking episodes in the past month. Abstinent for at least 2 weeks and no more than 4 weeks. Less than 20 lifetime cigarettes or equivalent. No history of addiction to any other substances or gambling. |
Behavioral: magnetic resonance imaging (MRI)
All subjects will undergo a baseline MRI and subjects in both alcohol groups (alcohol use disorder and combined alcohol and nicotine use disorder) will undergo a followup MRI 3 months after baseline.
|
Outcome Measures
Primary Outcome Measures
- Brain activation during functional magnetic resonance imaging (fMRI) in response to a probability and delay discounting task (PDD) [1 day]
An analysis of variance (ANOVA) test will be used to assess group differences (AUD, NUD, NAUD, and CS) in parametric brain activation during the PDD.
- Brain activation during functional magnetic resonance imaging (fMRI) in response to a stress modulated cue induced craving task (DSNBACK) [1 day]
An ANOVA will be used to assess group differences (AUD, NUD, NAUD, and CS) in brain activation that scales parametrically with the DSNBACK.
- Brain activation during resting state MRI. [1 day]
The magnitude of connectivity changes between groups during resting state will be assessed and reported using an ANOVA.
- Brain cortical density as assessed by voxel-based morphometry during MRI [1 day]
An ANOVA will be used to determine group differences.
- Brain white matter integrity as assessed by fractional anisotropy during MRI [1 day]
An ANOVA will be used to determine group differences
Eligibility Criteria
Criteria
Inclusion Criteria:
- None
Exclusion Criteria:
- None
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | VA Portland Health Care System, Portland, OR | Portland | Oregon | United States | 97239 |
Sponsors and Collaborators
- VA Office of Research and Development
- Oregon Health and Science University
Investigators
- Principal Investigator: William F Hoffman, MD PhD, VA Portland Health Care System, Portland, OR
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NURA-002-17S
- 17321